|
Key Signals · 1 trials updated
- Novo Nordisk | semaglutide | Phase NA (real-world) | NEW registration NCT07627074 (2026-06-04): 35,000-participant weight-loss real-world study in overweight/obesity; PrimaryCompletionDate listed as 2026-06-01 — predating registration — suggesting retrospective or registry-style enrollment
- Eli Lilly | eloralintide, orforglipron, retatrutide, macupatide | >12 Phase 1–3 trials batch-updated 2026-06-04; all show StatusVerifiedDate 2026-06 with no parameter changes — classified as routine mass verification sweep, NOISE
- Eli Lilly | orforglipron | Phase 3 ATTAIN-MAINTAIN (NCT06584916): COMPLETED status confirmed pre-window (v6, 2025-12-18; prior v5 was ACTIVE_NOT_RECRUITING); in-window v7 (2026-06-02) touched only administrative modules — NOISE, no actionable transition this cycle
- Amgen | maridebart cafraglutide (MariTide) | Phase 3 OSA (NCT07226765) and Phase 2 MASLD (NCT07441252) updated 2026-06-04; no status changes detected — routine updates
- Novo Nordisk | NNC0113-5840 (NCT07566390, Phase 1) and NNC0497-0040 (NCT07578584, Phase 1) updated 2026-06-04; both were first posted May 2026 (pre-window) — not new registrations, routine updates
|
|
Scan window: 2026-06-04 → 2026-06-05
MATERIAL
NCT07627074 — Novo Nordisk A/S | Semaglutide real-world study | Phase NA | NEW REGISTRATION
- StudyFirstPostDate: 2026-06-04 (within window — confirmed new registration)
- Title: "Weight Loss in Adults Using Semaglutide (Real-world Study)"
- Status: RECRUITING | Enrollment: 35,000 | Conditions: Overweight, Obesity
- Note: PrimaryCompletionDate listed as 2026-06-01, which predates the 2026-06-04 registration date. This strongly suggests the study is a retrospective or rolling real-world data registry rather than a prospective interventional trial. At 35,000 participants it would be one of the largest real-world obesity datasets for semaglutide.
- Priority sponsor new registration → material per process.
NOISE / NOT PROMOTED
NCT06584916 (Orforglipron ATTAIN-MAINTAIN, Eli Lilly, Phase 3): History confirmed COMPLETED transition at v6, 2025-12-18 (prior v5 2025-04-17 was ACTIVE_NOT_RECRUITING). In-window v7 (2026-06-02, posted 2026-06-04) changed Study Status + Study Description + Conditions + Eligibility + IPDSharing — administrative edits only. Not a new completion event this cycle.
Eli Lilly batch updates (12+ trials, 2026-06-04): eloralintide Phase 3 portfolio (NCT07282600, NCT07321886, NCT07353931, NCT07369011, NCT07392190), orforglipron Phase 3 portfolio (NCT07153471, NCT07202884, NCT07223593, NCT07241390), retatrutide Phase 3 (NCT07357415), macupatide combo Phase 2 (NCT07215559), SYNERGY-Outcomes MASLD Phase 3 (NCT07165028) — all show StatusVerifiedDate 2026-06 with no status transitions or enrollment changes. Pattern consistent with a company-wide annual/semi-annual verification sweep.
Amgen (NCT07226765, NCT07441252): Routine updates; RECRUITING unchanged, no parameter changes.
Novo Nordisk NNC0113-5840 and NNC0497-0040 Phase 1 trials: First posted May 2026 (before scan window); routine updates only.
SCOPE HYGIENE NOTE
Eloralintide (LY3841136) is being developed for MASLD via the Eli Lilly SYNERGY-Outcomes master protocol (NCT07165028, Phase 3, enrolled 4,500). This is an incretin-driven indication expansion outside the current obesity/T2DM scope. Consider adding MASLD/MASH as a condition to the painswick scope file if competitive monitoring of this indication is desired.
|